MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour

Summary

The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery. 20 participants will receive open label MRx0518 in a preliminary safety phase. After successful evaluation by the Independent Safety Monitoring Committee (IDMC), a further 100 participants will be recruited to receive MRx0518/Placebo.

Timeline

Start

2019-04-10

Primary completion

2022-12-31

Completion

2022-12-31

Drugs

Indications